Novavax (NVAX) Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
JPMorgan Downgrades Novavax (NVAX) to Neutral
May 12, 2021 5:45 AM EDTJPMorgan analyst Eric Joseph downgraded Novavax (NASDAQ: NVAX) from Overweight to Neutral with a price target of $161.00 (from $285.00).
The analyst comments "We are rated Neutral on NVAX shares. While topline UK phase 3 results reported to date have shown compelling efficacy, amid a series of clinical,... More
Novavax (NVAX) Tops Q1 EPS by 55c, Revenues Beat
May 10, 2021 4:04 PM EDTNovavax (NASDAQ: NVAX) reported Q1 EPS of ($3.05), $0.55 better than the analyst estimate of ($3.60). Revenue for the quarter came in at $447.23 million versus the consensus estimate of $233.9 million.
"Novavax made great strides over the first quarter to pave the path for our COVID-19 vaccine candidate, NVX-CoV2373,... More
